Arthur J. Tipton Named President of Controlled Release Society - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Arthur J. Tipton Named President of Controlled Release Society


Southern Research Institute announced that Arthur J. Tipton, president and CEO of Southern Research Institute, has been named president of the Controlled Release Society (CRS) for the 2014-2015 term. The inauguration took place at the Society's annual meeting on July 12 in Chicago with attendees from more than 40 countries. 

The Controlled Release Society is an international, interdisciplinary, not-for-profit organization whose guiding purpose is the advancement of delivery science and technology.

Tipton has worked in the pharmaceutical and biotechnology industries for more than 25 years and has pioneered the use of controlled release technologies through his work in polymer science and engineering, according to a Southern Research Institute.

"It is an honor to be named president of the Controlled Release Society," said Tipton in a statement. "Over the past several decades, controlled-release formulations have changed the treatment paradigm for a number of serious health conditions, including cancer, pain management, cardiovascular and central nervous system disorders, and have been involved in many industrial applications such as food flavorings and long acting fertilizers. As controlled release technologies continue to mature, industry and academia are meeting the challenges of developing the next generation of faster, safer, more accessible formulations, and CRS represents the world's leaders in advancing these novel techniques. I look forward to leading this distinguished and important group."

Previously Tipton held senior positions at Durect Corporation, its wholly-owned subsidiary Southern BioSystems, Birmingham Polymers, and Atrix Laboratories. In 2005, he founded Brookwood Pharmaceuticals, which was subsequently acquired by SurModics and later by Evonik. At Evonik, he served as senior vice president of the Birmingham Division and also led the company's global drug delivery program. Tipton has 31 issued U.S. patents, 22 published U.S. patent applications, and numerous foreign equivalents, with more than 70 presentations and publications.

Tipton earned a doctorate in polymer science and engineering from the University of Massachusetts in Amherst, and a bachelor of science degree in chemistry from Spring Hill College.

Source: Southern Research Institute

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here